Tags

Type your tag names separated by a space and hit enter

Single-dose desloratadine and montelukast and allergen-induced late airway responses.
Eur Respir J. 2009 Jun; 33(6):1302-8.ER

Abstract

Montelukast and desloratadine synergistically inhibit the allergen-induced early asthmatic response. Montelukast also suppresses the allergen-induced late asthmatic response, but there are no reports on the effect of desloratadine or the combination on the allergen-induced late asthmatic response. Atopic asthmatics (n = 10) completed a multicentric randomised double-blind crossover study comparing single-dose placebo, 5 mg desloratadine, 10 mg montelukast and the combination administered 2 h prior to allergen inhalation challenge. Methacholine challenges were performed 24 h before and after allergen challenge. Exhaled nitric oxide measurements and sputum inflammatory cell counts were also carried out. All active treatments significantly decreased the late asthmatic response area under the curve. Combination therapy provided the greatest inhibition compared to desloratadine and montelukast. Montelukast was nonsignificantly better than desloratadine but not as effective as the combination. There was a trend towards a decrease in airway responsiveness following montelukast and combination. Montelukast, but not desloratadine or the combination, decreased exhaled NO levels 24 h after allergen. The allergen-induced increase in sputum eosinophil numbers was significantly suppressed at 7 h with desloratadine and combination therapy, and at 24 h with montelukast and combination therapy. Single-dose co-administration of desloratadine and montelukast 2 h prior to allergen inhalation clinically abolished the late asthmatic response and eosinophil recruitment.

Authors+Show Affiliations

Dept of Pharmacology, Division of Respiratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada. beth.davis@usask.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

19164343

Citation

Davis, B E., et al. "Single-dose Desloratadine and Montelukast and Allergen-induced Late Airway Responses." The European Respiratory Journal, vol. 33, no. 6, 2009, pp. 1302-8.
Davis BE, Illamperuma C, Gauvreau GM, et al. Single-dose desloratadine and montelukast and allergen-induced late airway responses. Eur Respir J. 2009;33(6):1302-8.
Davis, B. E., Illamperuma, C., Gauvreau, G. M., Watson, R. M., O'Byrne, P. M., Deschesnes, F., Boulet, L. P., & Cockcroft, D. W. (2009). Single-dose desloratadine and montelukast and allergen-induced late airway responses. The European Respiratory Journal, 33(6), 1302-8. https://doi.org/10.1183/09031936.00169008
Davis BE, et al. Single-dose Desloratadine and Montelukast and Allergen-induced Late Airway Responses. Eur Respir J. 2009;33(6):1302-8. PubMed PMID: 19164343.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Single-dose desloratadine and montelukast and allergen-induced late airway responses. AU - Davis,B E, AU - Illamperuma,C, AU - Gauvreau,G M, AU - Watson,R M, AU - O'Byrne,P M, AU - Deschesnes,F, AU - Boulet,L P, AU - Cockcroft,D W, Y1 - 2009/01/22/ PY - 2009/1/24/entrez PY - 2009/1/24/pubmed PY - 2009/9/18/medline SP - 1302 EP - 8 JF - The European respiratory journal JO - Eur Respir J VL - 33 IS - 6 N2 - Montelukast and desloratadine synergistically inhibit the allergen-induced early asthmatic response. Montelukast also suppresses the allergen-induced late asthmatic response, but there are no reports on the effect of desloratadine or the combination on the allergen-induced late asthmatic response. Atopic asthmatics (n = 10) completed a multicentric randomised double-blind crossover study comparing single-dose placebo, 5 mg desloratadine, 10 mg montelukast and the combination administered 2 h prior to allergen inhalation challenge. Methacholine challenges were performed 24 h before and after allergen challenge. Exhaled nitric oxide measurements and sputum inflammatory cell counts were also carried out. All active treatments significantly decreased the late asthmatic response area under the curve. Combination therapy provided the greatest inhibition compared to desloratadine and montelukast. Montelukast was nonsignificantly better than desloratadine but not as effective as the combination. There was a trend towards a decrease in airway responsiveness following montelukast and combination. Montelukast, but not desloratadine or the combination, decreased exhaled NO levels 24 h after allergen. The allergen-induced increase in sputum eosinophil numbers was significantly suppressed at 7 h with desloratadine and combination therapy, and at 24 h with montelukast and combination therapy. Single-dose co-administration of desloratadine and montelukast 2 h prior to allergen inhalation clinically abolished the late asthmatic response and eosinophil recruitment. SN - 1399-3003 UR - https://www.unboundmedicine.com/medline/citation/19164343/Single_dose_desloratadine_and_montelukast_and_allergen_induced_late_airway_responses_ L2 - http://erj.ersjournals.com/cgi/pmidlookup?view=long&pmid=19164343 DB - PRIME DP - Unbound Medicine ER -